DDInter1867 DDInter1293
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Triflupromazine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Nilotinib
Triflupromazine {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Triflupromazine {u} (Compound) downregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Triflupromazine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Triflupromazine {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Triflupromazine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Triflupromazine {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is regulated by {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Triflupromazine {u} (Compound) downregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Triflupromazine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Triflupromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Triflupromazine (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is upregulated by Nilotinib (Compound)
Triflupromazine (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Nilotinib (Compound)
Triflupromazine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Triflupromazine (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) is downregulated by Nilotinib (Compound)
Triflupromazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may lead to a major life threatening interaction when taken with Nilotinib
Triflupromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Triflupromazine (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is regulated by HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Nilotinib (Compound)
Triflupromazine (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Triflupromazine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib